Short Communication

Association of the polymorphism Exon 1 (A/O) region of the mannose-binding lectin gene and periportal fibrosis regression in schistosomiasis after specific treatment

Saulo Gomes de Oliveira[1], Ilana Brito Ferraz de Souza[1], Taynan da Silva Constantino[1], Paula Carolina Valença Silva[1], Elker Lene Santos de Lima[2,3], Maria Tereza Cartaxo Muniz[2,3] and Ana Lúcia Coutinho Domingues[4]

[1]. Universidade Federal de Pernambuco, Centro Acadêmico de Vitória, Vitória de Santo Antão, PE, Brasil.
[2]. Universidade de Pernambuco, Centro de Oncohematologia Pediátrica, Recife, PE, Brasil.
[3]. Universidade de Pernambuco, Instituto de Ciências Biológicas, Recife, PE, Brasil.
[4]. Universidade Federal de Pernambuco, Departamento de Medicina Clínica, Recife, PE, Brasil.

Abstract

Introduction: We evaluated the association between genetic polymorphisms in exon 1 (A/O alleles) and promoter regions at positions -550 (H/L variant, rs11003125) and -221 (X/Y variant, rs7096206) MBL2 and periportal fibrosis regression. Methods: This was a retrospective cohort study involving 114 Brazilians infected with Schistosoma mansoni, who were subjected to follow-up for three years after specific treatment for schistosomiasis to estimate the probability of periportal fibrosis regression. Results: A risk association was observed between polymorphism at the exon 1 MBL2 and periportal fibrosis regression. Conclusions: This study suggests that the polymorphism of exon 1 MBL2 may potentially be used to predict periportal fibrosis regression in this population.

Keywords: Schistosomiasis. Periportal fibrosis. Mannose-binding lectin.

Periportal fibrosis (PPF) is the major pathological consequence of schistosomiasis. PPF is represented by an inflammatory and fibrotic response that occurs due to the presence of Schistosoma mansoni (SM) eggs in the liver, which can cause portal hypertension and, consequently, lead to the rupture of esophageal varices.

Some factors, such as consumption of alcohol, exposure to SM-contaminated areas (includes one-time exposure), specific treatment for SM, age, sex, and nutritional status of the individual may influence the progression of PPF. Additionally, the host immune response is considered an important factor in PPF pathogenesis.

In the fibrogenesis process, mannose-binding lectin (MBL) is related to the development of PPF. This protein plays an important role in activation of the complement system by binding the MBL/serine protease associated with MBL (MBL/MASP) and opsonization. MBL levels are higher in individuals with advanced periportal fibrosis.

Some polymorphisms identified in the promoter region of MBL2 -550 (H/L variant guanine to cytosine (G-C) nucleotide substitutions, rs11003125) and -221 (X/Y variant, C to G nucleotide substitution, rs7096206) and in the 5-untranslated region of exon 1 at position +4 (A/O variant, C to T nucleotide substitution (c.4T/C) or rs7095891) are responsible for functional alterations and influence the circulating concentration of MBL.

In the exon 1 region of MBL2, three polymorphisms are present in codons 52 (rs5030737), 54 (rs1800450), and 57 (rs1800451), which lead to the formation of three allelic variants, namely D, B, and C. These variant alleles are grouped into the “O” allele, and the normal allele is represented by “A”.

Additionally, in the promoter region of the MBL2 gene, mutations arise in the -550 region, which lead to the formation of
H/L alleles, where the nucleotide alteration from G to C occurs, and at position -221, X/Y alleles, wherein a similar nucleotide alteration occurs. The combination of alleles from these different regions of the MBL2 gene is called a haplotype. The union of alleles of the promoter region and exon 1 generates common haplotypes (HYPA, LYQA, LYPB, LQPC, and HYPD). The outcome of interest was the pattern of PPF regression identified by ultrasonography of the upper abdomen. The main exposures evaluated were polymorphisms in the exon 1 region and promoter regions -550 and -221 of the MBL2 gene, which, in the context of the hypothesis of this study, were investigated for associations with PPF regression. The pattern regression of PPF was considered the dependent variable. Therefore, the objective of this study was to investigate the association between clinical factors (sex, upper gastrointestinal bleeding (UGB), specific treatment, and contact with focus area) and polymorphisms of the exon 1 region as well as the promoter regions (-550 and -221) of the MBL2 with PPF regression after specific treatment in patients with SM in populations of endemic areas in the state of Pernambuco, northeastern Brazil.

This was a retrospective cohort study conducted from August 2016 to February 2019 to verify the association between MBL2 gene polymorphisms and PPF regression. A total of 114 patients infected with SM, who were inhabitants of an endemic area for schistosomiasis in the state of Pernambuco, northeastern Brazil, were enrolled and their cases were analyzed for three years retrospectively, before and after specific treatment for SM, to estimate the likelihood of PPF regression. A decrease in one pattern of PPF was maintained in subsequent ultrasound for three years.

All patients were divided into the following two groups: Group 1, exposed patients with genotypes (OO/OA exon 1; -550 HL, HH and -221 XY, XX); Group 2, not exposed patients with genotypes (AA exon 1; -550 LL and -221 YY). All individuals were older than 18 years and were assisted at the Outpatient Gastroenterology Clinic of the Hospital das Clinicas, Federal University of Pernambuco (HC-UFPF), Brazil. This study included subjects diagnosed with the hepatosplenic form of the disease with advanced PPF (pattern E or F) or with the hepatointestinal form of the disease with mild or moderate PPF (pattern C or D). The pattern of PPF was evaluated by abdominal ultrasound, using the Niamey protocol before and three years after treatment for schistosomiasis. This protocol classifies PPF cases based on patterns from A (normal) to F (very advanced).

Individuals with other associated liver diseases (hepatitis B, hepatitis C, alcoholic disease, steatosis) described in medical records and those with other clinical forms of schistosomiasis (pulmonary vascular disorders, pseudoneoplastic forms, schistosomal nephropathy, and schistosomal myeloradiculopathy) were excluded from this study. The outcome of interest was the pattern of PPF regression identified by ultrasonography of the upper abdomen. The main exposures evaluated were polymorphisms in the exon 1 region and promoter regions -550 and -221 of the MBL2 gene, which, in the context of the hypothesis of this study, were investigated for associations with PPF regression. The pattern regression of PPF was considered the dependent variable.

Information on these genotypes and haplotypes was obtained by real-time polymerase chain reaction (RT-PCR) and haplotypes were determined according to the methods reported by Garred et al. Other explanatory variables were gender, age, diagnosis of serious UGB, and contact with contaminated water by SM during the study period. Data were collected using a precoded structured questionnaire that was used for individuals by a single investigator. Follow-up was initiated from the period the specific treatment was first recorded and ended three years later. Crude relative risk (RR) and 95% confidence interval (95% CI) were used through univariate analysis (Chi-squared Yates corrected). The significance level was set at 0.05. Epi Info version 3.5.5 (CDC, Atlanta, GA, USA) was used for all statistical analyses.

The study was conducted according to the Declaration of Helsinki and approved by the Ethics and Research Committee of the Health Sciences Center of the Federal University of Pernambuco under protocol 113.199 and CAAE 03161512.6.0000.5208.

In this study, 139 patients were initially selected for convenience, of which 24 were excluded because they were not subjected to pre- and post-specific treatment ultrasound follow-up, and one was excluded due to associated pulmonary hypertension. Eight patients were excluded as there was no information available regarding the fibrosis pattern. Ultimately, 106 patients were enrolled in this study (Figure 1). As a few DNA samples obtained from six patients could not be amplified, they were not specifically analyzed for RT-PCR in the promoter regions (-550 and -221) and structural exon 1 of the MBL2 gene.
There was no difference in gender predominance, and the mean age was 57 years (SD: 11 years). In 64 (60%) patients, PPF was stable, in 21 (20%) decreased and in 21 (20%) increased. There was no association between sociodemographic and clinical variables and the PPF pattern of regression (Table 1).

A risk association was observed among individuals with MBL2 OO/AO genotypes (low and intermediate MBL expression, respectively; RR = 2.450; CI = 1.200-4.990, p-value = 0.015) and image pattern of PPF regression when compared to individuals with the AA genotype (high MBL expression) (Table 1). There was no association between promoter regions -550 and -221 MBL2 (RR = 1.035; CI = 0.853-1.257, p-value = 0.468 and RR = 0.893, CI = 0.741-1.077, p = 0.230, respectively) and MBL haplotypes and the image pattern of PPF regression (Table 1).

Although previous studies have established that several environmental factors (age, exposure frequency, parasite load, specific treatment, and level of education) influence the natural history of PPF\textsuperscript{11}, no evidence has been made available, to our

---

**TABLE 1:** Association between sociodemographic and clinical variables, the MBL2 gene polymorphisms in the promoter (-550, -221) and structural regions, MBL haplotypes, and the regression of the periportal fibrosis pattern in patients with schistosomiasis in the state of Pernambuco, Brazil.

| Characteristics                                      | Regression of the periportal fibrosis pattern | Yes (n = 21) | No (n = 85) | RR   | CI 95%               | p-value |
|------------------------------------------------------|-----------------------------------------------|--------------|-------------|------|----------------------|---------|
| **Sex**                                              |                                               |              |             |      |                      |         |
| Female                                               |                                               | 12           | 57          | 44   | 0.958 [0.793 - 1.157]| 0.421   |
| Male                                                 |                                               | 9            | 43          | 41   |                      |         |
| Total                                                |                                               | 21           | 100         | 85   |                      |         |
| **HDA**                                              |                                               |              |             |      |                      |         |
| No                                                   |                                               | 15           | 71          | 43   | 1 (reference)        |         |
| Yes                                                  |                                               | 6            | 29          | 42   | 2.069 [0.870 - 4.919]| 0.070   |
| Total                                                |                                               | 21           | 100         | 85   |                      |         |
| **Treatment for HDA**                                |                                               |              |             |      |                      |         |
| Not treated                                          |                                               | 14           | 67          | 39   | 1 (reference)        |         |
| Treated                                              |                                               | 7            | 33          | 46   | 0.847 [0.699 - 1.027]| 0.071   |
| Total                                                |                                               | 21           | 100         | 85   |                      |         |
| **Current contact with focus area**                  |                                               |              |             |      |                      |         |
| No                                                   |                                               | 20           | 95          | 78   | 1 (reference)        |         |
| Yes                                                  |                                               | 1            | 5           | 7    | 0.909 [0.687 – 1.204]| 0.468   |
| Total                                                |                                               | 21           | 100         | 85   |                      |         |
| **Contact with focus area after treatment**          |                                               |              |             |      |                      |         |
| No                                                   |                                               | 17           | 81          | 73   | 1 (reference)        |         |
| Yes                                                  |                                               | 4            | 19          | 12   | 1.081 [0.801 - 1.459]| 0.411   |
| Total                                                |                                               | 21           | 100         | 85   |                      |         |
| **Structural region (Exon 1) MBL**                    |                                               |              |             |      |                      |         |
| AA                                                   |                                               | 11           | 52          | 62   | 1 (reference)        |         |
| AO/ OO                                               |                                               | 10           | 48          | 23   | 2.450 [1.200 – 4.990]| 0.015   |
| Total                                                |                                               | 21           | 100         | 85   |                      |         |
| **Promoter region -221 MBL**                         |                                               |              |             |      |                      |         |
| YY                                                   |                                               | 16           | 84          | 59   | 1 (reference)        |         |
| XX/XY                                                |                                               | 3            | 16          | 22   | 0.893 [0.741 - 1.077]| 0.230   |
| Total                                                |                                               | 19           | 100         | 81   |                      |         |
| **Promoter region -550 MBL**                         |                                               |              |             |      |                      |         |
| LL                                                   |                                               | 6            | 32          | 29   | 1 (reference)        |         |
| HL/ HH                                               |                                               | 13           | 68          | 52   | 1.035 [0.853 – 1.257]| 0.468   |
| Total                                                |                                               | 19           | 100         | 81   |                      |         |
| **MBL haplotypes**                                   |                                               |              |             |      |                      |         |
| (LYO/LXO; LYO/LYO; HYA/LXO)                           |                                               |              |             |      |                      |         |
| High expression                                      |                                               | 8            | 42          | 42   | 1 (reference)        |         |
| Intermediate expression                              |                                               | 9            | 47          | 34   | 1.062 [0.873 - 1.291]| 0.365   |
| Low expression                                       |                                               | 2            | 11          | 5    | 1.176 [0.724 - 1.907]| 0.386   |
| Total                                                |                                               | 19           | 100         | 81   |                      |         |

*One hundred patients were evaluated for polymorphism in the promoter regions (-550, -221) in relation to MBL haplotypes, as six patients who did not present genotyping by DNA condition were excluded. HDA: upper digestive hemorrhage; EDA: endoscopic treatment; MBL: mannose-binding lectin; N: number of patients; RR: relative risk; CI: confidence interval; p-value.
knowledge, regarding the statistical association between the classic factors and PPF regression.

Similarly, Silva et al.4 evaluated 79 individuals infected with SM who presented different PPF patterns in the state of Pernambuco. They found no evidence of an association between classic factors and the severity of PPF. This suggests that there is a need for further cohort studies to assess other risk factors not addressed in this study to further explain the environmental risk factors in this population.

Some polymorphisms identified in promoter regions and in the exon 1 region of the MBL gene cause functional alterations and influence the serum concentration of this protein.7

In this study, evidence of risk association was found between the genotypes (AO/00) exon 1 MBL and the PPF pattern regression in this population, which is in agreement with reports that O0 homozygotes, AO heterozygotes, and AA homozygotes exhibit low MBL concentrations, intermediate concentrations, and elevated serum MBL concentrations, respectively.7

Similar results were reported by Constantino et al.,3 who analyzed 229 individuals infected with SM in Pernambuco, northeastern Brazil, and found that MBL serum concentrations were significantly higher in individuals with advanced PPF. They also identified a protective association between the A/O genotype of exon 1 MBL and elevated serum concentrations of MBL. They suggested that elevated MBL levels might contribute to liver damage in schistosomiasis and might be a predictive factor for PPF severity.

Similarly, Silva et al.4 evaluated 79 patients infected with SM in Pernambuco, northeastern Brazil, and found that higher serum concentrations of MBL were significantly associated with advanced PPF. They found no evidence of an association between classic factors and the severity of PPF. This suggests that there is a need for further cohort studies to assess other risk factors not addressed in this study to further explain the environmental risk factors in this population.

In this study, evidence of risk association was found between the genotypes (AO/00) exon 1 MBL and the PPF pattern regression in this population, which is in agreement with reports that O0 homozygotes, AO heterozygotes, and AA homozygotes exhibit low MBL concentrations, intermediate concentrations, and elevated serum MBL concentrations, respectively.7

Further, Pedroso et al.12 analyzed the impact of polymorphisms on the promoter and exon 1 MBL regions in 102 Euro-Brazilians with chronic hepatitis C and another group of seronegative controls composed of 102 individuals in Curitiba, southern Brazil. They found that MBL A/O genotypes were more frequent in patients with chronic hepatitis C compared to those in healthy control patients, and that low MBL levels might reduce the risk of chronic hepatitis C.

In contrast, Erdemir et al.13 found controversial results when analyzing the impact of exon 1 MBL polymorphisms on chronic hepatitis B (CHB) in 67 children with CHB and 99 healthy controls in Turkey. They found that genotype (OO) was substantially more frequent in children with CHB and that genotype (AO) was found predominantly in healthy control patients. They concluded that the homozygous genotype (OO) was associated with the development of chronic infection and the severity of liver disease.

In this study, there was no evidence of an association between MBL2 polymorphism promoters and the regression of PPF in this population. Considering the limitation of sample size in this study as well as possible ethnic variations in the population, further studies to explore the association between these polymorphisms and the regression of PPF are recommended.

A previous study reported that there was no association between genetic polymorphisms in exon 1 and promoter regions -221 and -550 of the MBL gene, with the PPF pattern. There was also no association between haplotypes of MBL and PPF severity. These findings might have been influenced by ethnic variations.3

Vallinoto et al.14 also investigated the impact of MBL gene polymorphisms on hepatitis C virus infections and compared 73 hepatitis C virus-infected patients and 92 seronegative controls in the Brazilian Amazon region. They found that there was no association between polymorphisms and disease progression. The authors considered the hypothesis that ethnic variations could have influenced these results.

The results reported in this study do not exclude the possibility that the MBL gene in other regions may influence PPF regression. Therefore, future studies with larger samples are warranted to better analyze these polymorphisms for improved assessment to ascertain an association between polymorphisms in the promoter region variants -550 and -221 MBL2 and PPF intensity, which may influence PPF regression after specific treatment for schistosomiasis.

Overall, we identified a risk association between the polymorphism at exon 1 MBL2 and PPF regression. Our results suggest that the polymorphism of exon 1 MBL2 may potentially be used to predict PPF regression in the Brazilian population.

ACKNOWLEDGMENTS

The authors thank the leadership of the Gastroenterology Clinic of the Hospital das Clínicas, Universidade Federal de Pernambuco, for allowing the selection of patients and the use of the Human Molecular Genetics Laboratories of the University of Pernambuco. This study was supported by the Universidade Federal de Pernambuco, Brazil. The authors acknowledge the support provided by Comissão de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

FINANCIAL SUPPORT

The Federal University of Pernambuco, Brazil, provided financial support for molecular biology experiments A.L.C. Domingues is supported by PROPEQ (23076. 019166.2012/63).

AUTHOR'S CONTRIBUTION

SGO: Conception and design of the study, Acquisition of data; IBFS: Conception and design of the study, Acquisition of data; TSC: Conception and design of the study, Acquisition of data; PCVS: Conception and design of the study, Analysis and interpretation of data, Final approval of the version to be submitted; ELSL: Conception and design of the study, Analysis and interpretation of data, Final approval of the version to be submitted; MTCM: Conception and design of the study, Analysis and interpretation of data, Final approval of the version to be submitted; ALC: Conception and design of the study, Acquisition of data, Drafting the article, Final approval of the version to be submitted.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

REFERENCES

1. Silva PCV, Gomes AV, Souza TK, Coelho MR, Cahu GG, Muniz MT, et al. Association of SNP (-G1082A) IL-10 with Increase in Severity of Periportal Fibrosis in Schistosomiasis, in the Northeast of Brazil. Genet Test Mol Biomarkers. 2014;18(9):646-52.
2. Silva PCV, Domingues ALC. Aspectos epidemiológicos da esquistossomose hepatoesplênica no Estado de Pernambuco, Brasil. Epidemiol Serv Saúde. 2011;20(3):327-36.

3. Constantino TS, Lima ELS, Brito LRPB, Silva JL, Coêlho MRCD, Muniz MTC, et al. Association Between Polymorphisms of the Manose-Binding Lectin and Severity of Periportal Fibrosis in Schistosomiasis, in the Northeast of Brazil. Genet Test Mol Biomarkers. 2017;21(9):571-76.

4. Silva PCV, Gomes AV, Cahu GGOM, Coêlho MRCD, Muniz MTC, Domingues ALC. Evaluation of the cytokine mannos-binding lectin as a mediator of periportal fibrosis progression in patients with schistosomiasis. Rev Soc Bras Med Trop. 2015;48(3):350-53.

5. Carvalho EG, Utiyama SRR, Kotze LMS, Reason ITM. Lectina ligante de manose (MBL): características biológicas e associação com doenças. Rev Bras Alerg Imunopatol. 2007;30(5):187-93.

6. Vinyals JGO, Alconero LL, Velasco PS, Alonso MAG, Ausín F, Fariñas MC, et al. Mannose-binding lectin promoter polymorphisms and gene variants in pulmonary tuberculosis patients from cantabria (northern Spain). Pulm Med. 2012;46:91-28.

7. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. Mannose-binding lectin and its genetic variants. Genes Immun. 2006;7(2):85-94.

8. Faria EJ, Faria IC, Ribeiro JD, Hessel G, Bertuzzo CS. Association of MBL2, TGF-beta1 and CD14 gene polymorphisms with lung disease severity in cystic fibrosis. J Bras Pneumol. 2009;35(4):334–42.

9. Richter J, Domingues ALC, Barata CH, Prata AR, Lambertucci JR. Report of the second satellite symposium on ultrasound in schistosomiasis. Mem Inst Oswaldo Cruz. 2001;96:151-56.

10. Garred P, Nielsen MA, Kurtzhals JA, Malhotra R, Madsen HO, Goka BQ, et al. Mannose-binding lectin is a disease modifier in clinical malaria and may function as opsonin for Plasmodium falciparum-infected erythrocytes. Infect Immun. 2003;71(9):5245–53.

11. Silva PCV, Leal TV, Domingues ALC. Treatment and education reduce the severity of schistosomiasis periportal fibrosis. Rev Soc Bras Med Trop. 2013;46(4):472-7.

12. Pedroso MLA, Boldt ABW, Ferrari LP, Steffensen R, Strauss E, Jensenius JC, et al. Mannose-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy. Clin Exp Immunol. 2008;152(2):258-64.

13. Erdemir G, Ozkan TB, Ozgur T, Budak F, Killic SS, Onay H. Mannose-Binding Lectin Gene Polymorphism and Chronic Hepatitis B Infection in Children. Saudi J Gastroenterol. 2015;21(2):84-89.

14. Vallinoto ACR, Silva RFP, Hermes RB, Amaral ISA, Miranda ECBM, Barbosa MSB, et al. Mannose-binding lectin gene polymorphisms are not associated with susceptibility to hepatitis C virus infection in the Brazilian Amazon region. Hum Immunol. 2009;70(9):754-7.